Amalgamated Bank Sells 612 Shares of Medpace Holdings, Inc. $MEDP

Amalgamated Bank decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.2% in the 2nd quarter, Holdings Channel reports. The fund owned 11,266 shares of the company’s stock after selling 612 shares during the quarter. Amalgamated Bank’s holdings in Medpace were worth $3,536,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in MEDP. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group grew its stake in shares of Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. grew its stake in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after acquiring an additional 35 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Medpace during the 1st quarter worth $60,000. Finally, IFP Advisors Inc grew its stake in shares of Medpace by 223.3% during the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after acquiring an additional 134 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of several research reports. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. William Blair reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. Jefferies Financial Group raised their target price on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research note on Tuesday, September 9th. Robert W. Baird set a $613.00 target price on Medpace in a research note on Friday, October 24th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a research note on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $475.90.

Medpace Stock Up 0.8%

Shares of NASDAQ MEDP opened at $584.91 on Monday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $625.00. The business has a 50-day simple moving average of $515.52 and a two-hundred day simple moving average of $403.46. The company has a market cap of $16.48 billion, a P/E ratio of 40.90, a P/E/G ratio of 2.67 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter last year, the company posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity

In other news, Director Cornelius P. Mccarthy III sold 1,662 shares of Medpace stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the sale, the director owned 10,197 shares in the company, valued at approximately $4,742,012.88. This trade represents a 14.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO August J. Troendle sold 36,196 shares of Medpace stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the sale, the chief executive officer owned 925,799 shares of the company’s stock, valued at approximately $440,587,744.10. This trade represents a 3.76% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 88,736 shares of company stock worth $47,286,494. Company insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.